Table 5.
Treatment strategies for ABMR episodes (n = 51)
| Treatment strategies | N (%) | |
|---|---|---|
| Acute ABMR | n = 19 | |
| Rituximab, IVIG, optimization, and/or steroid pulse | 5 (26.3%) | |
| Rituximab, PF/IA, steroid pulse, w/o IVIG | 4 (21.1%) | |
| Eculizumab or rituximab, thymoglobulin, PF/IA, steroid pulse | 3 (15.8%) | |
| Thymoglobulin, steroid pulse, PF/IA, or optimization | 2 (10.5%) | |
| Steroid pulse, w/o IVIG | 2 (10.5%) | |
| Optimization | 2 (10.5%) | |
| Bortezomib, rituximab, PF/IA, optimization, steroid pulse, IVIG | 1 (5.3%) | |
| Chronic active ABMR | n = 18 | |
| Rituximab, IVIG, optimization, and/or steroid pulse | 5 (27.8%) | |
| Optimization or no treatment | 4 (22.2%) | |
| Thymoglobulin, optimization, w/o steroid pulse | 2 (11.1%) | |
| Rituximab, PF/IA, optimization, IVIG, w/o steroid pulse | 2 (11.1%) | |
| IVIG, steroid pulse, optimization | 2 (11.1%) | |
| Bortezomib, steroid pulse, optimization | 1 (5.6%) | |
| Tocilizumab, PF/IA, IVIG, optimization | 1 (5.6%) | |
| Thymoglobulin, PF/IA, steroid pulse | 1 (5.6%) | |
| Mixed ABMR/TCMR | n = 14 | |
| Rituximab, PF/IA, steroid pulse, IVIG, and/or optimization | 5 (35.7%) | |
| Rituximab, steroid pulse, w/o IVIG, w/o optimization | 3 (21.4%) | |
| PF/IA, steroid pulse, w/o IVIG and optimization | 2 (14.3%) | |
| Eculizumab or thymoglobulin, rituximab, PF/IA, steroid pulse, IVIG, w/o optimization | 2 (14.3%) | |
| Steroid pulse, w/o IVIG and optimization | 2 (14.3%) |
ABMR antibody-mediated rejection, IVIG intravenous immunoglobulin G, PF plasmapheresis, IA immunoadsorption, Optimization increase or change of maintenance immunosuppression, w/o with or without